Literature DB >> 25783680

Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases.

Serdar Balci1, Olca Basturk2, Burcu Saka3, Pelin Bagci1, Lauren M Postlewait4, Takuma Tajiri5, Kee-Taek Jang6, Nobuyuki Ohike7, Grace E Kim8, Alyssa Krasinskas1, Hyejeong Choi6, Juan M Sarmiento9, David A Kooby4, Bassel F El-Rayes10, Jessica H Knight11, Michael Goodman11, Gizem Akkas1, Michelle D Reid1, Shishir K Maithel4, Volkan Adsay12.   

Abstract

BACKGROUND: Current nodal staging (N-staging) of ampullary carcinoma in the TNM staging system distinguishes between node-negative (N0) and node-positive (N1) disease but does not consider the metastatic lymph node (LN) number.
METHODS: Overall, 313 patients who underwent pancreatoduodenectomy for ampullary adenocarcinoma were categorized as N0, N1 (1-2 metastatic LNs), or N2 (≥3 metastatic LNs), as proposed by Kang et al. Clinicopathological features and overall survival (OS) of the three groups were compared.
RESULTS: The median number of LNs examined was 11, and LN metastasis was present in 142 cases (45 %). When LN-positive cases were re-classified according to the proposed staging system, 82 were N1 (26 %) and 60 were N2 (19 %). There was a significant correlation between proposed N-stage and lymphovascular invasion, perineural invasion, increased tumor size (each p < 0.001), and surgical margin positivity (p = 0.001). The median OS in LN-negative cases was significantly longer than that in LN-positive cases (107.5 vs. 32 months; p < 0.001). Patients with N1 and N2 disease had median survivals of 40 and 24.5 months, respectively (p < 0.0001). In addition, 1-, 3-, and 5-year survivals were 88, 76, 62 %, respectively, for N0; 90, 55, 31.5 %, respectively, for N1; and 68, 34, 30 %, respectively for N2 (p < 0.001). Even with multivariate modeling, the association between higher proposed N stage and shorter survival persisted (hazard ratio 1.6 for N1 and 1.9 for N2; p = 0.018).
CONCLUSIONS: Classification of nodal status in ampullary carcinomas based on the number of metastatic LNs has a significant prognostic value. A revised N-staging classification system should be incorporated into the TNM staging of ampullary cancers.

Entities:  

Mesh:

Year:  2015        PMID: 25783680      PMCID: PMC4575255          DOI: 10.1245/s10434-015-4499-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  57 in total

1.  Prognostic factors of carcinoma of the ampulla of Vater after surgery.

Authors:  Jianguo Zhou; Qian Zhang; Peng Li; Yi Shan; Dongbing Zhao; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-09-12

Review 2.  Ampullary cancer: an overview.

Authors:  Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  Pattern analysis of lymph node metastasis and the prognostic importance of number of metastatic nodes in ampullary adenocarcinoma.

Authors:  Jae Hoon Lee; Kyeong Geun Lee; Tae Kyung Ha; Young Jin Jun; Seung Sam Paik; Hwon Kyum Park; Kwang Soo Lee
Journal:  Am Surg       Date:  2011-03       Impact factor: 0.688

4.  Surgical outcomes and prognostic factors for ampulla of Vater cancer.

Authors:  S B Choi; W B Kim; T J Song; S O Suh; Y C Kim; S Y Choi
Journal:  Scand J Surg       Date:  2011       Impact factor: 2.360

5.  Carcinoid tumors of the duodenum and ampulla of vater: a clinicomorphologic, immunohistochemical, and cell kinetic comparison.

Authors:  L Bornstein-Quevedo; A Gamboa-Domínguez
Journal:  Hum Pathol       Date:  2001-11       Impact factor: 3.466

6.  Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms.

Authors:  Hui-Ping Hsu; Yan-Shen Shan; Ying-Tai Jin; Ming-Derg Lai; Pin-Wen Lin
Journal:  J Surg Oncol       Date:  2010-04-01       Impact factor: 3.454

7.  Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.

Authors:  Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo
Journal:  Surgery       Date:  2006-08-28       Impact factor: 3.982

8.  DNA ploidy as a major prognostic factor in resectable ampulla of Vater cancers.

Authors:  Y M Shyr; C H Su; L H Wu; A F Li; J H Chiu; W Y Lui
Journal:  J Surg Oncol       Date:  1993-08       Impact factor: 3.454

9.  Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma.

Authors:  Massimo Falconi; Stefano Crippa; Ismael Domínguez; Giuliano Barugola; Paola Capelli; Stefano Marcucci; Stefania Beghelli; Aldo Scarpa; Claudio Bassi; Paolo Pederzoli
Journal:  Ann Surg Oncol       Date:  2008-08-20       Impact factor: 5.344

10.  Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?

Authors:  Arne Westgaard; Ewa Pomianowska; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Ann Surg Oncol       Date:  2012-09-07       Impact factor: 5.344

View more
  9 in total

Review 1.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

2.  Use of Nodal Staging Score in Evaluating the Accuracy of Pathologic Nodal Status in Node-Negative Ampullary Carcinoma.

Authors:  Xi-Tai Huang; Chen-Song Huang; Jian-Hui Li; Qiong-Cong Xu; Xiao-Yu Yin
Journal:  J Gastrointest Surg       Date:  2020-04-06       Impact factor: 3.452

3.  The Role of Log Odds of Positive Lymph Nodes in Predicting the Survival after Resection for Ampullary Adenocarcinoma.

Authors:  Cihan Agalar; Anıl Aysal; Tarkan Unek; Tufan Egeli; Mucahit Ozbilgin; Nesrin Akturk; Huseyin Salih Semiz; Tugba Unek; Mesut Akarsu; Müjde Soyturk; Hulya Ellidokuz; Ozgul Sagol; Ibrahim Astarcioglu
Journal:  Pathol Oncol Res       Date:  2019-01-28       Impact factor: 3.201

4.  Determining the Adequate Examined Lymph Node Count in Resected Ampullary Adenocarcinoma-A National Cohort Study.

Authors:  Ibrahim Nassour; Alana Christie; Michael A Choti; John C Mansour; Rebecca M Minter; Patricio M Polanco; Mathew M Augustine; Matthew R Porembka; Xian-Jin Xie; Sam C Wang
Journal:  J Gastrointest Surg       Date:  2018-03-15       Impact factor: 3.452

5.  Prognostic value of the lymph node metastasis in patients with ampulla of Vater cancer after surgical resection.

Authors:  Jeong Woo Lee; Sae Byeol Choi; Tae Wan Lim; Wan Joon Kim; Pyoungjae Park; Wan Bae Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-02-28

6.  Predictive value of metabolic activity detected by pre-operative 18F FDG PET/CT in ampullary adenocarcinoma.

Authors:  Young Mok Park; Hyung Il Seo
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

7.  Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy.

Authors:  Xiaojie Zhang; Chongyuan Sun; Zefeng Li; Tongbo Wang; Lulu Zhao; Penghui Niu; Chunguang Guo; Yingtai Chen; Xu Che; Dongbing Zhao
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

8.  Validation of T Stage According to Depth of Invasion and N Stage Subclassification Based on Number of Metastatic Lymph Nodes for Distal Extrahepatic Bile Duct (EBD) Carcinoma.

Authors:  Ahrim Moon; Dong Wook Choi; Seoung Ho Choi; Jin Seok Heo; Kee-Taek Jang
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.

Authors:  Michael Feretis; Tengyao Wang; Satheesh Iype; Adam Duckworth; Rebecca Brais; Bristi Basu; Neville V Jamieson; Emmanuel Huguet; Anita Balakrishnan; Asif Jah; Raaj K Praseedom; Simon J Harper; Siong-Seng Liau
Journal:  Pancreas       Date:  2017 Nov/Dec       Impact factor: 3.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.